Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
It is very uncertain whether carbamazepine changes benzodiazepine discontinuation, longest compared with placebo (very low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, end of intervention · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether carbamazepine changes rescue analgesic consumption compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
1 finding from 1 review
Leaving the study early · patients with schizophrenia
It is very uncertain whether adjunctive carbamazepine + antipsychotics changes acceptability of treatment Leaving the study early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
Adjunctive carbamazepine + antipsychotics showed no clear difference in no clinically important change in general mental state Scale used:… compared with placebo/no adjunctive treatment + antipsychotics (low certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia
1 finding from 1 review
Depressive symptoms · patients with schizophrenia
1 finding from 1 review
Aggression · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Carbamazepine · adults and children with focal seizures
1 finding from 1 review
Time to treatment failure (any reason related to treatment) All participants ‐ adjusted by seizure type Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to treatment failure (any reason related to treatment) All… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: focal onset seizures Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate probably leads to higher time to treatment failure (any reason related to treatment)Subgroup:… compared with carbamazepine (moderate certainty).
1 finding from 1 review
Time to treatment failure (any reason related to treatment) Subgroup: generalised onset tonic‐clonic seizures or unclassified epilepsy Range of · adults and children with newly onset partial or generalised epilepsy
Topiramate showed no clear difference in time to treatment failure (any reason related to treatment)… compared with carbamazepine (low certainty).
1 finding from 1 review